Preferred Label : Autologous iCasp9-deltaNGFR-CD19CAR-expressing T Cells;
NCIt synonyms : Autologous iC9.2A.deltaNGFR.2A.CAR.CD19 T Cells; Autologous ICASP9-deltaNGFR-CD19CAR-expressing T-Lymphocytes;
NCIt definition : A preparation of autologous T-lymphocytes that are transduced with a retroviral vector
encoding a chimeric antigen receptor (CAR) specific for the CD19 antigen, the suicide
gene, inducible human caspase 9 (iCasp9 or iC9), and a truncated low-affinity nerve
growth factor receptor (deltaNGFR), with potential immunomodulating and antineoplastic
activities. The iCasp9 construct consists of the entire coding sequence for the human
FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked
to the gene encoding human caspase 9, which is deleted of its endogenous caspase activation
and recruitment domains. Upon intravenous administration, autologous iCasp9-deltaNGFR-CD19CAR-expressing
T cells are selectively toxic to CD19-expressing tumor cells. If the administered
T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be
administered, which binds to the FKBP12-F36V drug binding domain, activates caspase
9, and results in apoptosis of the administered CAR19 T-cells. The CD19 antigen is
a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Prior to administration, deltaNGFR, is used to select the CAR19-transduced T-cells
for further enrichment by flow cytometry using an anti-NGFR antibody.;
NCI Metathesaurus CUI : CL513770;
Origin ID : C131214;
UMLS CUI : C4329370;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
